Ladikou E E, Sivaloganathan H, Pepper A, Chevassut T
Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PS, UK.
Royal Sussex County Hospital, Brighton, BN2 5BE, UK.
Curr Oncol Rep. 2020 Feb 11;22(3):27. doi: 10.1007/s11912-020-0885-0.
Acute myeloid leukaemia (AML) is a heterogeneous malignancy for which treatment options remain suboptimal. It is clear that a greater understanding of the biology of the AML niche will enable new therapeutic strategies to be developed in order to improve treatment outcomes for patients.
Recent evidence has highlighted the importance of the bone marrow microenvironment in protecting leukaemia cells, and in particular leukaemic stem cells from chemotherapy-induced cell death. This includes mesenchymal stem cells supporting growth and preventing apoptosis, and altered action and secretion profiles of other niche components including adipocytes, endothelial cells and T cells. Here, we provide a detailed overview of the current understanding of the AML bone marrow microenvironment. Clinical trials of agents that mobilise leukaemic stem cells from the bone marrow are currently ongoing and show early promise. Future challenges will involve combining these novel therapies targeted at the AML niche with conventional chemotherapy treatment.
急性髓系白血病（AML）是一种异质性恶性肿瘤，其治疗选择仍不尽人意。显然，对AML微环境生物学有更深入的了解将有助于开发新的治疗策略，以改善患者的治疗效果。
最近的证据强调了骨髓微环境在保护白血病细胞，特别是白血病干细胞免受化疗诱导的细胞死亡方面的重要性。这包括间充质干细胞支持生长并防止细胞凋亡，以及其他微环境成分（包括脂肪细胞、内皮细胞和T细胞）的作用和分泌谱改变。在此，我们详细概述了目前对AML骨髓微环境的认识。目前正在进行从骨髓中动员白血病干细胞的药物的临床试验，并显示出早期前景。未来的挑战将涉及将这些针对AML微环境的新型疗法与传统化疗相结合。
Zotero 插件